NAS:CTNM (USA)
Â
Class A Common Stock
$
15.18
+0.365 (+2.46%)
01:13 PM EST
Warning! GuruFocus detected
1 Severe warning sign
with CTNM.
Try a 7-Day Free Trial
to check it out.
Business Description
Contineum Therapeutics Inc
NAICS : 541713
SIC : 2833
Share Class Description:
CTNM: Class A Common StockDescription
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 218.86 | |||||
| Equity-to-Asset | -0.52 | |||||
| Debt-to-Equity | -0.01 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.86 | |||||
| 9-Day RSI | 42.32 | |||||
| 14-Day RSI | 45.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 23.29 | |||||
| Quick Ratio | 23.29 | |||||
| Cash Ratio | 22.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -8.15 | |||||
| ROA % | -7.28 | |||||
| ROIC % | -159.81 | |||||
| ROC (Joel Greenblatt) % | -488.2 | |||||
| ROCE % | -7.94 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.38 | |||||
| EV-to-EBIT | -31.58 | |||||
| EV-to-EBITDA | -31.73 | |||||
| EV-to-Revenue | 5.01 | |||||
| EV-to-FCF | -60.29 | |||||
| Earnings Yield (Greenblatt) % | -3.17 | |||||
| FCF Yield % | -1.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTNM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Contineum Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 50 | ||
| EPS (TTM) ($) | -0.287 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 45.06 | ||
| 14-Day ATR ($) | 1.155283 | ||
| 20-Day SMA ($) | 15.3785 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 13.27 - 16.06 | ||
| Shares Outstanding (Mil) | 25.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Contineum Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Contineum Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Contineum Therapeutics Inc Frequently Asked Questions
What is Contineum Therapeutics Inc(CTNM)'s stock price today?
The current price of CTNM is $15.18. The 52 week high of CTNM is $16.06 and 52 week low is $13.27.
When is next earnings date of Contineum Therapeutics Inc(CTNM)?
The next earnings date of Contineum Therapeutics Inc(CTNM) is .
Does Contineum Therapeutics Inc(CTNM) pay dividends? If so, how much?
Contineum Therapeutics Inc(CTNM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers